requested.

Claims 1-16 and 18-50 are currently pending in the application. Claims 18, 22, and 23 are allowed. Claim 17 has been cancelled. Claims 1, 16, 19, 28 and 49 are amended as recommended by the Examiner to overcome objections to the claims. Claims 10, 11, 21, 24, 25, 26, and 27 have been amended to overcome the Examiner's rejection under 35 U.S.C. § 112, second paragraph. Support for the above amendments to the claims if found in the specification and claims as originally filed. No new matter has been entered.

Claims 10, 11, 21, and 24-50 are rejected under 35 U.S.C. § 112, second paragraph as being indefinite.

By the above amendments to the claims the Applicants assert that the rejection has been rendered moot. Accordingly withdrawal of the rejection is requested.

Having addressed all of the Examiner's objections and rejections, the Applicants assert that the application is now in condition for allowance. Accordingly, early and

B

favorable notice of to that effect is respectfully requested. If the Examiner has any questions regarding this application or the present amendment to the application a telephone call to the undersigned is respectfully requested.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: _____

Perry E. Van Over
Reg. No. 42,197
Tel. No.: (202) 861-3545
Fax No.: (202) 822-0944

1100 New York Ave., N.W.
Ninth Floor - East Tower
Washington, D.C. 20005
(202) 861-3000

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

The claims are amended as follows:

1. (Amended) A monitoring device for use in conjunction with one or more body fluid testing devices to provide an indication of the time of maximum fertility in the mammalian ovulation cycle, said monitoring device comprising:

a) a reading means for reading for reading test signals provided by said one or more testing devices, said reading means being operationally connected to said testing devices, said signals including a signal proportional to the concentration of a first analyte in a body fluid, which first analyte exhibits a detectable concentration change at about the time of ovulation in said cycle, and a signal proportional to the concentration of a second analyte in a sample of body fluid, which second analyte exhibits a detectable concentration change after the commencement of said cycle but before the concentration change of said first analyte becomes detectable; and

b) an electronic processing means for interpreting said test signals obtained in [as] a series of tests conducted following the commencement of said cycle, wherein said electronic processing means of said monitoring device is operationally connected to said reading means, said electronic processing means providing an indication that fertility is elevated when said concentration change of said second analyte has been detected, and an indication that fertility

B

is maximum when said concentration change of said first analyte has been detected.

10 11. (Twice Amended) A monitoring device according to claim 1 including interface means for communicating with transmitting means for transmitting electronic data [transmission means].

11. (Amended) A monitoring device according to claim 10, wherein said [electronic data transmission] transmitting means is a semi-conductor memory device.

16. (Amended) A test kit according to claim 15 wherein said ovulation cycle is the human ovulation cycle, said body fluid is urine, said first analyte is LH and said second analyte is E3G.

19. (Amended) A method according to claim 18, wherein an analyte selected from the group consisting of estradiol and metabolites thereof are detected in the same body fluid samples as [are] is used in the LH tests.

24 25. (Twice Amended) A test kit according to claim 22, wherein the electronic monitor includes interface means for communicating with [electronic data transmission] a transmitting means for transmitting electronic data.

25. (Amended) A test kit according to claim 24, wherein said [electronic data transmission]

B

transmitting means is selected from the group consisting of a smart card and a floppy disk.

26. (Amended) A test kit according to claim 24, wherein said [electronic data transmission] transmitting means is a semi-conductor memory device.

27. (Twice Amended) A method of patient management comprising testing a patient by analysis of a body fluid of said patient, wherein said analysis is accomplished by:

(i) providing:

a) one or more testing devices that provide test signals, including a signal proportional to the concentration of a first analyte in a body fluid, which first analyte exhibits a detectable concentration change at about the time of ovulation in said cycle, and a signal proportional to the concentration of a second analyte in a sample of body fluid, which second analyte exhibits a detectable concentration change after the commencement of said cycle but before the concentration change of said first analyte becomes detectable;

b) a monitoring device comprising receiving means for receiving one of said one or more testing devices, reading means associated with said receiving means for reading said test signals, electronic processing means for interpreting said test signals, and interface means for communicating with electronic data transmission means; and

c) electronic data transmission means for transmitting electronic data;

(ii) downloading electronic data from said monitoring device onto said electronic data transmission means;

(iii) inputting said downloaded electronic data into said [computer] electronic

B

processing means, from which said [computer] electronic processing means a health professional thereby derives patient-related information.

28. (Amended) A method according to claim 27, wherein said electronic data transmission means is a semi-conductor memory device.

49. (Amended) A method according to claim 27, wherein said electronic data transmission means is interfaced with said [monitor] monitoring device to download a result of a specific test for which a specific testing device is provided.

B